|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
4
|
1264
|
April 21, 2026
|
|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
190
|
April 21, 2026
|
|
Etelcalcetide Nitroamide – is this possible?
|
|
0
|
101
|
April 18, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
176
|
April 14, 2026
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
13
|
1784
|
April 9, 2026
|
|
Society of Toxicology STO 2026 -Posters
|
|
1
|
147
|
April 7, 2026
|
|
Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy-Pub
|
|
0
|
164
|
March 23, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
99
|
March 20, 2026
|
|
Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products-Pub
|
|
5
|
587
|
February 17, 2026
|
|
N-Nitroso methylphenidate anybody?
|
|
1
|
352
|
February 12, 2026
|
|
N-Nitroso Imidazole content in Clotrimazole
|
|
9
|
829
|
February 9, 2026
|
|
N-nitroso clonixin
|
|
3
|
197
|
February 6, 2026
|
|
NDSRI in Pyrathiazine theocolate
|
|
3
|
391
|
December 5, 2025
|
|
Role of Carbonyl Compounds for N-Nitrosamine Formation during Nitrosation: Kinetics and Mechanisms
|
|
1
|
592
|
November 27, 2025
|
|
N-Nitrosamine Formation in Pharmaceutical Drug Products: Development and Validation of a Biased, Conservative, Predictive Model-Pub
|
|
4
|
622
|
November 24, 2025
|
|
Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018–2025)-Pub
|
|
0
|
272
|
November 18, 2025
|
|
N nitroso urapidil
|
|
0
|
109
|
November 18, 2025
|
|
Nitrosamine Control: From Risk Assessment to Analytical Testing with Emphasis on Sample Preparation and Phase-Appropriate Method Validation-Pub
|
|
0
|
402
|
November 8, 2025
|
|
Sample Prep for Complex Matrices - creams etc?
|
|
1
|
202
|
October 10, 2025
|
|
Monitoring the Concentration of Nitrogen Oxides in the Fluidized Bed Drying/Granulation Process and Evaluation of Reduction Methods
|
|
2
|
675
|
September 28, 2025
|
|
A Simple and Scalable Synthesis of N-Nitroso Salbutamol Impurities A, D, and F -Pub
|
|
1
|
256
|
September 27, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
5595
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
539
|
September 4, 2025
|
|
N-nitrosamines: in silico modelling of DNA reactivity and identification of metabolic precursors
|
|
0
|
174
|
August 12, 2025
|
|
Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling
|
|
1
|
172
|
August 7, 2025
|
|
Nitrosamine Formation with Lidocaine in Ointments and Injections
|
|
1
|
582
|
August 5, 2025
|
|
Synthesis of Nitroso Derivatives of Dihydropyridine Calcium Channel Blockers
|
|
5
|
1038
|
July 31, 2025
|
|
Alignment between Duplex Sequencing and transgenic rodent mutation assay data in the assessment of in vivo NDMA-induced mutagenesis-Pub
|
|
0
|
159
|
July 21, 2025
|
|
Can anybody have scientific rationale about the non formation of N-nitroso-amlodipine
|
|
3
|
904
|
July 18, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
287
|
July 12, 2025
|